Hologic Inc. (NASDAQ:HOLX)‘s stock had its “outperform” rating reaffirmed by research analysts at Leerink Swann in a research report issued to clients and investors on Monday. They presently have a $46.00 price target on the stock. Leerink Swann’s target price indicates a potential upside of 17.50% from the company’s current price.
Several other research analysts have also weighed in on the stock. Piper Jaffray Cos. set a $40.00 price objective on shares of Hologic and gave the stock a “hold” rating in a research note on Monday, July 25th. They noted that the move was a valuation call. Barclays PLC upgraded shares of Hologic from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $42.00 to $44.00 in a research note on Friday, September 23rd. Evercore ISI upgraded shares of Hologic from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $38.00 to $42.00 in a research note on Thursday, July 28th. Canaccord Genuity set a $45.00 price target on shares of Hologic and gave the company a “buy” rating in a research note on Thursday, July 28th. Finally, Jefferies Group upped their price target on shares of Hologic from $42.00 to $43.00 and gave the company a “buy” rating in a research note on Thursday, July 28th. Six equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $42.71.
Hologic (NASDAQ:HOLX) opened at 39.15 on Monday. The stock has a 50 day moving average of $38.33 and a 200-day moving average of $36.13. Hologic has a 1-year low of $31.84 and a 1-year high of $41.66. The company has a market cap of $10.86 billion, a PE ratio of 43.16 and a beta of 1.00.
Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Wednesday, July 27th. The company reported $0.51 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.03. The company had revenue of $717.40 million for the quarter, compared to analyst estimates of $703.66 million. Hologic had a net margin of 9.39% and a return on equity of 26.25%. Hologic’s revenue for the quarter was up 3.4% compared to the same quarter last year. During the same period in the previous year, the business earned $0.43 EPS. On average, equities research analysts predict that Hologic will post $1.94 earnings per share for the current year.
In other news, Director Nancy Leaming sold 8,179 shares of the company’s stock in a transaction that occurred on Thursday, July 21st. The shares were sold at an average price of $37.00, for a total transaction of $302,623.00. Following the completion of the sale, the director now owns 67,140 shares of the company’s stock, valued at approximately $2,484,180. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.84% of the company’s stock.
Several hedge funds have recently modified their holdings of HOLX. Mizuho Asset Management Co. Ltd. increased its stake in shares of Hologic by 89.9% in the second quarter. Mizuho Asset Management Co. Ltd. now owns 3,313 shares of the company’s stock worth $115,000 after buying an additional 1,568 shares during the period. J.Safra Asset Management Corp purchased a new stake in shares of Hologic during the second quarter worth $115,000. Invictus RG increased its stake in shares of Hologic by 577.0% in the second quarter. Invictus RG now owns 3,791 shares of the company’s stock worth $131,000 after buying an additional 3,231 shares during the period. Thompson Siegel & Walmsley LLC increased its stake in shares of Hologic by 1.2% in the second quarter. Thompson Siegel & Walmsley LLC now owns 4,176 shares of the company’s stock worth $144,000 after buying an additional 51 shares during the period. Finally, Synovus Financial Corp increased its stake in shares of Hologic by 35.6% in the second quarter. Synovus Financial Corp now owns 4,950 shares of the company’s stock worth $171,000 after buying an additional 1,300 shares during the period. 94.51% of the stock is owned by institutional investors.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. Its Diagnostics products include its Aptima family of assays, which run on its advanced instrumentation systems (Panther and Tigris); ThinPrep system; the Rapid Fetal Fibronectin Test, and Procleix blood screening assays.
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.